VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., May 14, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced the following scientific presentations:
Conference
20th European Congress on Obesity (ECO), Arena and Convention Centre Liverpool (UK)
 
Date / Time / Details
Poster Number: T5:P.106
Track Number: 5 
Session Date: Monday, May 13, 2013
Presentation Time: 1315 – 1445 hrs
 
Presentation Title
Does a History of Depression and/or Antidepressant Use Affect the Weight Loss Efficacy of Phentermine and Topiramate Extended-Release?
 
Authors
Patrick M. O'Neil, PhD a; Timothy Church, MD b; Barbara Troupin, MD, MBA c
 
Affiliations:
aMedical University of South Carolina, Charleston, SC
bPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA
cVIVUS, Inc., Mountain View, CA
 
Date / Time / Details
Presentation Date: Wednesday, May 15, 2013
Presentation Location: Hall 7
Session Time: 0945 – 1115 hrs
Presentation Time: 1000 – 1015 hrs
 
Presentation Title
Weight Loss and Improvements in Hypertension Status Associated With Phentermine and Topiramate Extended-Release Treatment in Obese and Overweight Adults
 
Authors
Nick Finer, MBBS, BSc, FRCP a Jens Jordan, MD b Roman V. Dvorak, MD, PhD c
 
Affiliations: 
aInstitute for Cardiovascular Science, University College London, UK
bInstitute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
cVIVUS, Inc., Mountain View, CA

About Qsymia

Qsymia ® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

If you liked this article you might like

Insider Trading Alert - MAR, EVER And VVUS Traded By Insiders

Insider Trading Alert - MDSO, KAI And VVUS Traded By Insiders

Insider Trading Alert - OMAM, CBOE And VVUS Traded By Insiders

Insider Trading Alert - SBCF, VVUS And ACN Traded By Insiders

Vivus (VVUS) Strong On High Relative Volume Today